Show simple item record

dc.contributor.authorRoberts, A.W.
dc.contributor.authorThomas, Andrew
dc.contributor.authorRees, A.
dc.contributor.authorEvans, M.
dc.date.accessioned2008-10-17T11:25:43Z
dc.date.available2008-10-17T11:25:43Z
dc.date.issued2003-12-01en_UK
dc.identifier.citationCurrent Opinion in Lipidology, 14 (6), pp.567-573en_UK
dc.identifier.issn0957-9672en_UK
dc.identifier.urihttp://hdl.handle.net/10369/404
dc.description.abstractPurpose of review: The prevalence of type 2 diabetes globally is reaching epidemic proportions. Type 2 diabetes is strongly associated with increased risk of cardiovascular disease. Atherosclerosis is thought to arise as a result of a chronic inflammatory process within the arterial wall. Insulin resistance is central to the pathogenesis of type 2 diabetes and may contribute to atherogenesis, either directly or through associated risk factors. The peroxisome proliferator-activated receptor-γ agonists, the thiazolidinediones, pioglitazone and rosiglitazone, are insulin sensitizing agents, that are licensed for the management of hyperglycaemia. Growing evidence supports an array of additional effects of thiazolidinedione therapy, both immunomodulatory and antiinflammatory, which may attenuate atherogenesis in type 2 diabetes. Recent findings: Studies have shown that thiazolidinedione therapy may lead to risk factor modulation in type 2 diabetes. Thiazolidinediones treatment has been shown to reduce blood pressure, modify the atherogenic lipid profile associated with type 2 diabetes, reduce microalbuminuria and ameliorate the prothrombotic diathesis. Further evidence suggests that thiazolidinediones therapy inhibits the inflammatory processes which may be involved in atherosclerotic plaque initiation, propagation and destabilization. Summary: Modification of insulin resistance by thiazolidinedione therapy in type 2 diabetes and the range of pleiotropic effects may not only impact on incident type 2 diabetes, but also on associated cardiovascular disease. Numerous large clinical endpoint studies are under way to investigate these issues.
dc.publisherLippencott Williams and Wilkinsen_UK
dc.relation.ispartofseriesCurrent Opinion in Lipidologyen_UK
dc.titlePeroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directionsen_UK
dc.identifier.doihttp://dx.doi.org/10.1097/00041433-200312000-00004en_UK


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record